Tag Archive for: Otsuka Pharmaceutical


While Otsuka Pharmaceutical can expect to a drop in sales as its schizophrenia therapy Abilify Maintena (aripiprazole) loses its market exclusivity later this year, the recently approved longer-acting formulation Abilify Asimtufii will help the company buttress its revenues, according to a report Wednesday from data analytics and consulting firm GlobalData.